



THE PAEDIATRIC SOCIETY OF  
NEW ZEALAND

Secretariat: Denise Tringham  
P O Box 22 234  
Wellington 6441  
Tel: (04) 938 4827  
Fax: (04) 976 4827  
Email: [denise@paediatrics.org.nz](mailto:denise@paediatrics.org.nz)  
Website: [www.paediatrics.org.nz](http://www.paediatrics.org.nz)

26 April 2013

Ms Geraldine MacGibbon  
Senior Therapeutic Group Manager  
Pharmac  
PO Box 10 254  
Wellington 6143

[Geraldine.macgibbon@pharmac.govt.nz](mailto:Geraldine.macgibbon@pharmac.govt.nz)

Dear Ms MacGibbon

**Re: Proposal to widen access to Adalimumab**

Thank you for the opportunity to comment on this proposal, which we were pleased to see.

I will provide some comments and queries on behalf of the Paediatric Gastroenterology Special Interest Group (Paediatric Society NZ). I will not make any comments on the use of this drug for rheumatological indications.

**Comment 1:** The listing for the initial use of Adalimumab for fistulising Crohn disease (CD) initially states that approvals will be valid for a 6 month period, but that a maximum of 4 months supply will be provided.

**Comment 2:** With regards Fistula Assessment at baseline and subsequently, is the intention to use the Fistula Assessment Form as used by Medicare Australia?

**Comment 3:** With regards the Renewal listing requirements: if the Medicare Assessment Form is used (as above), then the comment about induration and patient-perceived pain would appear to be superfluous as these details are included in the assessment process already.

Thank you for the opportunity to comment on, and to write in regards to, this consultation document.

Yours sincerely

Professor Andrew S Day  
For Gastroenterology, Hepatology and Nutrition SIG